Innogen Pharmaceuticals announced on November 19, 2026, an exclusive licensing and commercialization agreement with Arcera Life Sciences for efsubaglutide alfa, Innogen's internally developed glucagon-like peptide-1 (GLP-1) receptor agonist, in selected international markets.¹ Arcera gains exclusive rights in selected countries across Africa, Eastern Europe, Latin America, and the Middle East, while Innogen retains rights in the rest of the world.¹
Key facts
- Drug: efsubaglutide alfa (Innogen Pharmaceuticals)
- Class: Ultra-long-acting GLP-1 receptor agonist (human GLP-1 analogue and IgG Fc fusion protein)
- Half-life: Average up to 280 hours across studies
- Licensee: Arcera Life Sciences (Abu Dhabi, United Arab Emirates)
- Territory: Selected countries in Africa, Eastern Europe, Latin America, and the Middle East
- Upfront and near-term: $38 million, including a $15 million non-refundable upfront payment
- Total potential value: More than $1 billion, plus tiered royalties up to a double-digit percentage
- Current approval: Type 2 diabetes in mainland China and Macao; on China's 2025 reimbursement list
- Obesity data: 10.6% average weight reduction at 18 weeks with 20 mg weekly (phase 2b ENLIGHT)
- Other studies: Phase 2b/3 SUPER 2 in type 2 diabetes; completed phase 2 of monthly dosing in Australia
“By combining Innogen's scientific innovation with Arcera's strengths in international regulatory affairs and commercialization, we aim to broaden access to differentiated therapies and ultimately improve the quality of life of patients around the world,” said Qinghua Wang, MD, PhD, founder, chairman, and chief executive officer of Innogen Pharmaceuticals, in a company press release.¹
What are the financial terms of the Innogen and Arcera deal?
Innogen will receive $38 million in upfront and near-term milestone payments, including a non-refundable upfront payment of $15 million.¹ It is also eligible for sales milestone payments and tiered royalties at rates of up to a double-digit percentage of aggregate annual net sales in the territory, with total potential deal value exceeding $1 billion.¹
What is efsubaglutide alfa and how does it work?
Efsubaglutide alfa is a fusion protein combining a human GLP-1 analogue with an immunoglobulin G (IgG) Fc fragment and has an average half-life of up to 280 hours across studies.¹ It is approved for type 2 diabetes in mainland China and Macao and is included in China's National Reimbursement Drug List (2025 version).¹ Innogen says monotherapy reduced hemoglobin A1c (HbA1c) by 1.1 percentage points after 4 weeks, with a reduction of up to 2.2 percentage points at week 24, and may help protect pancreatic beta-cell function.¹
In the randomized, double-blind, placebo-controlled phase 2b/3 SUPER 2 trial, published in Nature Communications, efsubaglutide alfa added to metformin improved glycemia alongside beta-cell functional responses in adults with type 2 diabetes.²
How much weight loss did efsubaglutide alfa achieve in obesity studies?
In the phase 2b ENLIGHT study in Chinese adults with overweight or obesity, participants receiving 20 mg once weekly for 18 weeks achieved an average body-weight reduction of 10.6% and a waist-circumference reduction of approximately 8.9 cm, while those receiving 20 mg every 2 weeks achieved an average reduction of 9.7%.¹ Muscle-to-fat ratio increased by up to 45.3% from baseline with weekly dosing, and liver fat content fell by up to 51.8%.¹ Innogen said gastrointestinal adverse events were low relative to other GLP-1 receptor agonists based on cross-trial comparisons, and no participants discontinued because of adverse events during the 18-week treatment period.¹ Innogen has also completed a phase 2 trial of once-monthly dosing in Australia.¹